Beetham Thomas W.

CIK 00017413823 companiesWALTHAM, MA

SEC Profile

Transactions

Companies

Filings

CIK

0001741382

Recent Transactions

38 trades

Award
Viridian Therapeutics, Inc.\DE$VRDN
Restricted Stock Units
2025-03-03+37,636→ 37,636 total
Award
Viridian Therapeutics, Inc.\DE$VRDN
Stock Option (Right to Buy)
2025-03-03+225,814→ 225,814 total
Purchase
Viridian Therapeutics, Inc.\DE$VRDN
Common Stock
2024-09-27$23.41/sh+5,000→ 6,000 total
Award
Viridian Therapeutics, Inc.\DE$VRDN
Stock Option (Right to Buy)
2023-10-30+474,400→ 474,400 total
Award
Dianthus Therapeutics, Inc. /DE/$DNTH
Common Stock
2022-11-30$0.94/sh+3,000→ 19,897 total
Award
Dianthus Therapeutics, Inc. /DE/$DNTH
Stock Option (Right to Buy)
2022-08-01+75,000→ 75,000 total
Award
Dianthus Therapeutics, Inc. /DE/$DNTH
Common Stock
2022-05-31$0.99/sh+3,000→ 16,897 total
Award
Dianthus Therapeutics, Inc. /DE/$DNTH
Stock Option (Right to Buy)
2022-05-17+50,000→ 50,000 total
Award
Dianthus Therapeutics, Inc. /DE/$DNTH
Stock Option (Right to Buy)
2022-02-15+75,000→ 75,000 total
Sale
Dianthus Therapeutics, Inc. /DE/$DNTH
Common Stock
2021-09-16$6.73/sh−6,103→ 13,897 total
Award
Dianthus Therapeutics, Inc. /DE/$DNTH
Common Stock
2021-09-14+20,000→ 20,000 total
Award
Dianthus Therapeutics, Inc. /DE/$DNTH
Stock Option (Right to Buy)
2021-06-14+200,000→ 200,000 total
Award
Kiniksa Pharmaceuticals International, plc$KNSA
Restricted Share Units
2021-03-20+4,287→ 4,287 total
Award
Kiniksa Pharmaceuticals International, plc$KNSA
Restricted Share Units
2021-03-20+5,855→ 5,855 total
Award
Kiniksa Pharmaceuticals International, plc$KNSA
Restricted Share Units
2021-03-16+8,769→ 8,769 total
Award
Kiniksa Pharmaceuticals International, plc$KNSA
Share Option
2021-03-16+52,611→ 52,611 total
Sale
Kiniksa Pharmaceuticals International, plc$KNSA
Class A Common Shares
2021-02-03$22.09/sh−2,477→ 297,523 total
Conversion
Kiniksa Pharmaceuticals International, plc$KNSA
Class A Common Shares
2021-02-03+300,000→ 300,000 total
Conversion
Kiniksa Pharmaceuticals International, plc$KNSA
Class B Common Shares
2021-02-03−300,000→ 114,157 total
Award
Kiniksa Pharmaceuticals International, plc$KNSA
Share Option
2020-09-10+75,000→ 75,000 total
Sale
Kiniksa Pharmaceuticals International, plc$KNSA
Class A Common Shares
2020-07-01$25.32/sh−26,734→ 2,855 total
Sale
Kiniksa Pharmaceuticals International, plc$KNSA
Class A Common Shares
2020-07-01$25.84/sh−2,855→ 0 total
Exercise/Conversion
Kiniksa Pharmaceuticals International, plc$KNSA
Share Option
2020-06-10−13,752→ 112,189 total
Exercise/Conversion
Kiniksa Pharmaceuticals International, plc$KNSA
Class A Common Shares
2020-06-10$1.59/sh+13,752→ 43,341 total
Sale
Kiniksa Pharmaceuticals International, plc$KNSA
Class A Common Shares
2020-06-10$25.07/sh−13,752→ 29,589 total
Sale
Kiniksa Pharmaceuticals International, plc$KNSA
Class A Common Shares
2020-04-21$20.44/sh−955→ 29,589 total
Sale
Kiniksa Pharmaceuticals International, plc$KNSA
Class A Common Shares
2020-04-21$19.56/sh−1,563→ 30,544 total
Sale
Kiniksa Pharmaceuticals International, plc$KNSA
Class A Common Shares
2020-04-20$19.06/sh−47,423→ 32,107 total
Award
Kiniksa Pharmaceuticals International, plc$KNSA
Share Option
2020-03-13+75,000→ 75,000 total
Sale
Kiniksa Pharmaceuticals International, plc$KNSA
Class A Common Shares
2020-02-14$18.58/sh−59→ 79,530 total
Award
Kiniksa Pharmaceuticals International, plc$KNSA
Share Option
2019-09-17+45,000→ 45,000 total
Award
Kiniksa Pharmaceuticals International, plc$KNSA
Share Option
2019-03-04+42,000→ 42,000 total
Award
Kiniksa Pharmaceuticals International, plc$KNSA
Share Option
2018-09-20+45,000→ 45,000 total
Conversion
Kiniksa Pharmaceuticals International, plc$KNSA
Class A Common Shares
2018-05-29+6,392→ 79,589 total
Conversion
Kiniksa Pharmaceuticals International, plc$KNSA
Class B Common Shares
2018-05-29+48,172→ 414,157 total
Conversion
Kiniksa Pharmaceuticals International, plc$KNSA
Series C Preferred Shares
2018-05-29−6,392→ 0 total
Conversion
Kiniksa Pharmaceuticals International, plc$KNSA
Series A Preferred Shares
2018-05-29−48,172→ 0 total
Purchase
Kiniksa Pharmaceuticals International, plc$KNSA
Series C Preferred Shares
2018-02-09$15.64/sh+6,392→ 6,392 total

Companies

Recent Filings

Address

C/O VIRIDIAN THERAPEUTICS, INC. 221 CRESCENT STREET, SUITE 103A

WALTHAM, MA, 02453

View on SEC.gov